SCHEDULE: Orca Capital AG Discloses 9.9% Stake in 60 Degrees Pharmaceuticals
Beneficial Ownership Report
Orca Capital AG has reported a 9.9% beneficial ownership stake in 60 Degrees Pharmaceuticals, Inc., holding 320,000 shares of common stock.
Summary
- Orca Capital AG, a German entity, has filed a Schedule 13G indicating beneficial ownership of 320,000 shares of Common Stock in 60 Degrees Pharmaceuticals, Inc.
- This ownership represents 9.9% of the Issuer's outstanding Common Stock.
- The calculation of the ownership percentage is based on an aggregate of 3,226,205 shares of Common Stock outstanding immediately after the completion of the Issuer's registered offering.
- Orca Capital AG holds sole voting power and sole dispositive power over all 320,000 shares.
- The filing notes that Orca Capital AG also holds 789,474 shares issuable upon exercise of warrants and 74,737 shares issuable upon exercise of pre-funded warrants, but these are subject to a 4.99% blocker.
- The 4.99% blocker prevents the Reporting Person from exercising warrants or pre-funded warrants if it would result in beneficial ownership exceeding 4.99% of the Issuer's outstanding Common Stock.
Sentiment
Score: 5
Explanation: The document is a factual disclosure of beneficial ownership and does not contain information that would inherently indicate positive or negative sentiment regarding the company's performance or outlook.
Future Outlook
The document does not provide any forward-looking statements or guidance regarding the company's future performance or strategic direction.
Industry Context
This filing is a standard disclosure of a significant ownership stake by an institutional investor in a publicly traded pharmaceutical company. It does not provide broader industry trends or competitive analysis.
Corporate Governance
| Change Type | Description | Effective Date | Impact Assessment |
|---|---|---|---|
| Ownership Structure Detail | The reporting person's ability to exercise warrants and pre-funded warrants is subject to a 4.99% blocker, preventing them from beneficially owning more than 4.99% of the Issuer's outstanding Common Stock after any such exercise. | N/A | This provision limits the extent to which Orca Capital AG can increase its direct ownership stake through the exercise of existing warrants and pre-funded warrants, potentially influencing future capital structure and control dynamics. |
Stakeholder Impact
- Shareholders: The disclosure of a new significant shareholder (Orca Capital AG) holding 9.9% of the common stock provides transparency regarding the company's ownership structure. This can influence investor perception and potentially liquidity.
- Company Management: Awareness of a significant institutional holder may influence strategic decisions and engagement with the investor base.
Key Dates
| Date | Description |
|---|---|
| 07/15/2025 | Date of event which requires filing of this statement |
| 07/16/2025 | Date of Issuer's Prospectus filing pursuant to Rule 424(b)(4) with the SEC |
| 07/17/2025 | Date of Schedule 13G signature by Orca Capital AG |
Keywords
60 Degrees Pharmaceuticals, Orca Capital AG, Schedule 13G, Beneficial Ownership, Common Stock, SEC Filing, Shareholder, Investment, Warrants, Pre-funded Warrants
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.